Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy Article

Hellmann, Matthew D, Janne, Pasi A, Opyrchal, Mateusz et al. (2021). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy . CLINICAL CANCER RESEARCH, 27(4), 1019-1028. 10.1158/1078-0432.CCR-20-3305

Open Access Industry Collaboration

cited authors

  • Hellmann, Matthew D; Janne, Pasi A; Opyrchal, Mateusz; Hafez, Navid; Raez, Luis E; Gabrilovich, Dmitry; Wang, Fang; Trepel, Jane B; Lee, Min-Jung; Yuno, Akira; Lee, Sunmin; Brouwer, Susan; Sankoh, Serap; Wang, Lei; Tamang, David; Schmidt, Emmett; Meyers, Michael L; Ramalingam, Suresh S; Shum, Elaine; Ordentlich, Peter

sustainable development goals

authors

publication date

  • February 15, 2021

webpage

published in

keywords

  • ACQUIRED-RESISTANCE
  • CELL LUNG-CANCER
  • CRITERIA
  • IMMUNE-CHECKPOINT BLOCKADE
  • INHIBITION
  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • AMER ASSOC CANCER RESEARCH

start page

  • 1019

end page

  • 1028

volume

  • 27

issue

  • 4